Article
Oncology
Guillaume Cartron, Emmanuel Bachy, Herve Tilly, Nicolas Daguindau, Gian-Matteo Pica, Fontanet Bijou, Christiane Mounier, Aline Clavert, Gandhi Laurent Damaj, Borhane Slama, Olivier Casasnovas, Roch Houot, Krimo Bouabdallah, David Sibon, Olivier Fitoussi, Nadine Morineau, Charles Herbaux, Thomas Gastinne, Luc-Matthieu Fornecker, Corinne Haioun, Vincent Launay, Carla Araujo, Omar Benbrahim, Laurence Sanhes, Remy Gressin, Hugo Gonzalez, Franck Morschhauser, David Ternant, Luc Xerri, Karin Tarte, Delphine Pranger
Summary: Rituximab improves progression-free survival and time to next treatment for patients with low-tumor burden follicular lymphoma. However, prolonged maintenance may raise concerns about resources use and patient adhesion. This study investigates the use of short rituximab maintenance using the subcutaneous route.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Max L. Goldman, Jimmy J. Mao, Christopher S. Strouse, Wanqi Chen, Manali Rupji, Zhengjia Chen, Matthew J. Maurer, Oscar Calzada, Michael Churnetski, Christopher R. Flowers, James R. Cerhan, Brian K. Link, Carrie A. Thompson, Jonathon B. Cohen
Summary: The study found limited role for routine surveillance imaging in FL patients who complete front-line therapy. Future studies should evaluate which patients may benefit from a more aggressive surveillance approach and explore novel methods of relapse detection.
Article
Oncology
Sharmila Raghunandan, Melinda Pauly, William G. Blum, Muna Qayed, Madhav Dhodapkar, Mohamed Elkhalifa, Benjamin Watkins, Michelle Schoettler, Edwin Horwitz, Suhag Parikh, Shanmuganathan Chandrakasan, Kathryn Leung, Elyse Bryson, Laura Deeb, Jonathan L. Kaufman, Diana Worthington-White, Adina Alazraki, Jordan M. Schecter, Deepu Madduri, Carolyn C. Jackson, Enrique Zudaire, Agne Taraseviciute-Morris, Alexander Babich, Tonia Nesheiwat, Martin Vogel, Nikoletta Lendvai, Lida Pacaud, Kirsten M. Williams
Summary: Plasmablastic lymphoma (PBL) is a rare subtype of aggressive large B-cell lymphoma that has a poor prognosis. Treatment options are limited and new approaches are needed. This case report highlights the successful use of chimeric antigen receptor T-cell (CAR-T) therapy targeting B-cell maturation antigen (BCMA) in a patient with refractory PBL, resulting in a complete remission without severe adverse effects. This supports the consideration of immunotherapy as a potential treatment option for refractory PBL.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Review
Medicine, Research & Experimental
Emmanuel Bachy, Kaspar Rufibach, Joana Parreira, Aino Launonen, Tina Nielsen, Allan Hackshaw
Summary: The improved outcomes in first-line treatment of FL have made it challenging to demonstrate further treatment benefits in trials. New endpoints are needed to reflect long remission times, low relapse rates, and the impact of subsequent therapies in FL.
ADVANCES IN THERAPY
(2021)
Article
Immunology
William A. Fisher, Vladimir Gilca, Michelle Murti, Alison Orth, Hartley Garfield, Paul Roumeliotis, Emmanouil Rampakakis, Vivien Brown, John Yaremko, Paul Van Buynder, Constantina Boikos, James A. Mansi
Summary: This study aims to understand how the funding status influences parental perceptions of approved but unfunded vaccines and their intentions to vaccinate. The results show that the funding status strongly influences parents' beliefs about the necessity, safety, and efficacy of vaccination.
Article
Biochemistry & Molecular Biology
Nathan Hale Fowler, Michael Dickinson, Martin Dreyling, Joaquin Martinez-Lopez, Arne Kolstad, Jason Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie Jose Kersten, Charalambos Andreadis, Peter A. Riedell, P. Joy Ho, Jose Antonio Perez-Simon, Andy Chen, Loretta J. Nastoupil, Bastian von Tresckow, Andres Jose Maria Ferreri, Takanori Teshima, Piers E. M. Patten, Joseph P. McGuirk, Andreas L. Petzer, Fritz Offner, Andreas Viardot, Pier Luigi Zinzani, Ram Malladi, Aiesha Zia, Rakesh Awasthi, Aisha Masood, Oezlem Anak, Stephen J. Schuster, Catherine Thieblemont
Summary: Tisagenlecleucel, an autologous anti-CD19 CAR-T cell therapy, demonstrated a high complete response rate of 69.1% and overall response rate of 86.2% in adults with relapsed or refractory follicular lymphoma. Adverse events post-treatment primarily included cytokine release syndrome and neurological events, with no treatment-related deaths reported.
Article
Oncology
John C. Byrd, Peter Hillmen, Paolo Ghia, Arnon P. Kater, Asher Chanan-Khan, Richard R. Furman, Susan O'Brien, Mustafa Nuri Yenerel, Arpad Illes, Neil Kay, Jose A. Garcia-Marco, Anthony Mato, Javier Pinilla-Ibarz, John F. Seymour, Stephane Lepretre, Stephan Stilgenbauer, Tadeusz Robak, Wayne Rothbaum, Raquel Izumi, Ahmed Hamdy, Priti Patel, Kara Higgins, Sophia Sohoni, Wojciech Jurczak
Summary: In this study, acalabrutinib was found to be noninferior to ibrutinib in terms of progression-free survival in patients with CLL, with a lower incidence of cardiovascular adverse events. This suggests that acalabrutinib may be a more tolerable option for continuous therapy in this patient population.
JOURNAL OF CLINICAL ONCOLOGY
(2021)
Review
Oncology
Kyu-Hye Choi, Seung-Jae Lee, So-Hwa Mun, Jin-Ho Song, Byung-Ock Choi
Summary: This systematic review and meta-analysis aimed to evaluate the role of consolidative radiation therapy (RT) in patients with advanced-stage DLBCL who achieved complete remission after R-CHOP immunochemotherapy. The analysis included six retrospective studies and showed that consolidative RT was associated with improved overall survival and disease-free survival compared to no RT. Further research is needed to determine the optimal radiation fields and indications for consolidative RT in the rituximab era for advanced-stage DLBCL patients.
Article
Hematology
G. Tjitske Los-deVries, Wendy B. C. Stevens, Erik van Dijk, Carole Langois-Jacques, Andrew J. Clear, Phylicia Stathi, Margaretha G. M. Roemer, Matias Mendeville, Nathalie J. Hijmering, Birgitta Sander, Andreas Rosenwald, Maria Calaminici, Eva Hoster, Wolfgang Hiddemann, Philippe Gaulard, Gilles Salles, Heike Horn, Wolfram Klapper, Luc Xerri, Catherine Burton, Reuben M. Tooze, Alexandra G. Smith, Christian Buske, David W. Scott, Yasodha Natkunam, Ranjana Advani, Laurie H. Sehn, John Raemaekers, John Gribben, Eva Kimby, Marie Jose Kersten, Delphine Maucort-Boulch, Bauke Ylstra, Daphne de Jong
Summary: The genomic and immune microenvironmental features of follicular lymphoma (FL) differ between stage I and stage III/IV, with distinct differences in cell populations and mutations. This exploratory study provides new insights into the heterogeneity of FL and its underlying oncogenic pathways.
Article
Oncology
Uffe Klausen, Nicolai Gronne Dahlager Jorgensen, Jacob Handlos Grauslund, Shamaila Munir Ahmad, Anne Ortved Gang, Evelina Martinenaite, Stine Emilie Weis-Banke, Marie Fredslund Breinholt, Guy Wayne Novotny, Julie Westerlin Kjeldsen, Morten Orebo Holmstrom, Lone Bredo Pedersen, Christian Bjorn Poulsen, Per Boye Hansen, Ozcan Met, Inge Marie Svane, Carsten Utoft Niemann, Lars Moller Pedersen, Mads Hald Andersen
Summary: The study showed that vaccination with PD-L1 and PD-L2 peptides in FL patients can induce vaccine-specific immune responses, with some patients experiencing injection site reactions and mild flu-like symptoms. Additionally, some patients achieved complete remission or long-term disease regression during vaccination. Further investigation into the potential clinical efficacy of this dual-epitope vaccine in a larger study is warranted.
Review
Radiology, Nuclear Medicine & Medical Imaging
Sally F. Barrington, Farheen Mir, Tarec Christoffer El-Galaly, Andrea Knapp, Tina G. Nielsen, Denis Sahin, Michael Wenger, Lale Kostakoglu, Judith Trotman, Michel Meignan
Summary: Complete metabolic response (CMR) on PET/CT is an independent predictor of overall survival in first-line treatment of high-tumor-burden follicular lymphoma. Patients who do not achieve CMR have poorer outcomes, with those with a Deauville score of 5 showing shorter progression-free survival and time to next treatment than those with a score of 4.
JOURNAL OF NUCLEAR MEDICINE
(2022)
Article
Hematology
Juan Jose Rodriguez-Sevilla, Concepcion Fernandez-Rodriguez, Leyre Bento, Ramon Diez-Feijoo, Sergio Pinzon, Joan Gibert, Lierni Fernandez-Ibarrondo, Marta Lafuente, Ana Ferrer, Blanca Sanchez-Gonzalez, Eva Gimeno, Juan Sainz, Rafael Ramos, Juan F. Garcia, Lluis Colomo, Beatriz Bellosillo, Antonio Gutierrez, Antonio Salar
Summary: Four clinical or clinicogenetic-risk models were explored in patients with symptomatic FL who received frontline immunochemotherapy. The FLIPI remains the clinical risk score with higher discrimination in patients with advanced FL treated with immunochemotherapy, but the performance of the m7-FLIPI should be further investigated in patients treated with R-B.
Article
Immunology
Sheikh Mohammad Fazle Akbar, Mamun Al Mahtab, Julio Cesar Aguilar, Osamu Yoshida, Sakirul Khan, Eduardo Penton, Guillen Nieto Gerardo, Yoichi Hiasa
Summary: The objective of this study was to assess the safety and efficacy of a therapeutic vaccine (NASVAC) in patients with chronic hepatitis B (CHB) three years after the end of treatment (EOT). The results of the follow-up showed that NASVAC is a safe and effective treatment for CHB.
Article
Medicine, General & Internal
Xiaonan Hong, Yuqin Song, Yuankai Shi, Qingyuan Zhang, Wei Guo, Gang Wu, Junmin Li, Jifeng Feng, Anastasiia Kinkolykh, Andrea Knapp, Tongyu Lin
Summary: This study reports the results of a subgroup of Chinese patients with follicular lymphoma (FL), and the findings are consistent with the global population, indicating a positive benefit-risk profile of G-chemo in Chinese FL patients.
CHINESE MEDICAL JOURNAL
(2022)
Article
Medicine, General & Internal
Adam M. Kase, Mohamed A. Kharfan Dabaja, Andrew Donaldson, Jamie Elliott, Taimur Sher
Summary: This study reports a case of relapsed follicular lymphoma after CAR-T therapy, which achieved complete remission after receiving other treatments, providing a promising treatment option for patients in the post-CAR-T setting.
CLINICAL CASE REPORTS
(2022)
